Biopharmaceuticals Global Business Report 2024 with Focus on 200+ Select Players Including Abbott, Amgen, Biogen, Eli Lilly and Co, F. Hoffmann-La Roche, J&J, Merck, Novo Nordisk, Pfizer, Sanofi
23 août 2024 07h20 HE
|
Research and Markets
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
US Biosimilar Market Research 2024-2028 Featuring Leading Players - Pfizer, Novartis, Amgen, Samsung Biologics, Celltrion, and Viatris
12 août 2024 05h28 HE
|
Research and Markets
Dublin, Aug. 12, 2024 (GLOBE NEWSWIRE) -- The "US Biosimilar Market: Insights & Forecast (2024-2028)" report has been added to ResearchAndMarkets.com's offering.The US biosimilar market is...
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
11 juil. 2024 08h00 HE
|
Samsung Bioepis
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
Biosimilars Training Course (2-Days Online: October 1-2, 2024) - Global Considerations and Strategies for Biotech/Biosimilar Products and Regulatory Pathways in EU and US
03 juil. 2024 11h25 HE
|
Research and Markets
Dublin, July 03, 2024 (GLOBE NEWSWIRE) -- The "Biosimilars Training Course" conference has been added to ResearchAndMarkets.com's offering. Prepare for the biosimilar market growth as some of the...
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara
01 juil. 2024 02h03 HE
|
Samsung Bioepis
PYZCHIVA becomes Samsung Bioepis’ seventh biosimilar and fourth immunology biosimilar approved by the FDAPYZCHIVA’s licensing period will begin on February 22, 2025, in the United States, based on the...
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation
25 juin 2024 09h00 HE
|
Samsung Bioepis
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation
Biosimilars Training Course: Prepare for Growth as Some of the World's Best-known Biologics Face Patent Expiration in the Coming Years (ONLINE EVENT)
20 juin 2024 04h55 HE
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Biosimilars Training Course" conference has been added to ResearchAndMarkets.com's offering. Prepare for the biosimilar market growth as some of the...
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024
14 juin 2024 03h00 HE
|
Samsung Bioepis
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congre
Global Biosimilar Contract Manufacturing Market Forecast 2024-2034 | A Projected $48.67 Billion Opportunity with Profiles of 10+ Leading Market Players | Oncology Applications in North America Dominate
05 juin 2024 03h36 HE
|
Research and Markets
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Global Biosimilar Contract Manufacturing Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The...
Global Biosimilars and Follow-On Biologics Market Report 2024-2034 - Expanding the Portfolio of Biosimilars for Rare Diseases
31 mai 2024 06h46 HE
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Biosimilars and Follow-On Biologics Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Biosimilars and...